MedTrace Logo

NCT Neuro Master Match - N²M² (NOA-20)

NCT03158389 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2023-09-28

No results posted yet for this study

Summary

The objective of N²M² is the improvement of overall survival of patients with glioblastoma with an unmethylated MGMT promoter based on molecular characterization and use of targeted compounds in a modern trial design. The progression-free survival rate at six months (PFS-6) will be used to make decisions.

Conditions

  • Glioblastoma, Adult

Interventions

DRUG

APG101

weekly i.v.

DRUG

Alectinib

twice daily (oral)

DRUG

Idasanutlin

orally on 5 days of a 28 days cycle

DRUG

Atezolizumab

i.v. every 3 weeks

DRUG

Vismodegib

daily orally

DRUG

Temsirolimus

weekly i.v.

DRUG

Palbociclib

orally on 21 days of a 28 days cycle

Sponsors & Collaborators

  • German Cancer Aid

    collaborator OTHER

  • German Cancer Research Center

    collaborator OTHER

  • National Center for Tumor Diseases, Heidelberg

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Wolfgang Wick, Prof. Dr. · University Hospital Heidelberg

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2023-02-22
Completion
2023-02-22

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03158389 on ClinicalTrials.gov